Hearing testimony from a group of diverse experts from the fields of bioethics, theology, law, technology transfer, engineering, and various fields in science and medicine, the Presidential Commission for the Study of Bioethical Issues met at Penn on September 13-14.
If the popularity of the prime-time sitcom “The Big Bang Theory” or the number of television programs produced in the Star Trek franchise (6!) says anything about popular culture, it's that science is not necessarily the enemy of fun. For the skeptics who need proof that science can be dramatic, inspiring and accessible, there is the Penn Science Café, now in its fifth season.
Structure of Key Molecule in Immune System Provides Clues for Designing Drugs, According to Penn Study
PHILADELPHIA - A team from the University of Pennsylvania School of Medicine and Utrecht University has deciphered a key step in an evolutionarily old branch of the immune response. This system, called complement, comprises a network of proteins that “complement” the work of antibodies in destroying foreign invaders. It serves as a rapid defense mechanism in most species from primitive sponges to humans.
PHILADELPHIA – Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors’ signals halt tumor progression in some patients. However, not all patients’ tumors respond, with some becoming resistant over time. Different drugs that interfere with other steps in the signaling pathway may improve the response of patients, yet little is known about these molecules.
Les Shaw and John Trojanowski of the School of Medicine are cited for their contributions to an early diagnosis for Alzheimer’s.